CA3104054A1 - Bicyclic heteroaromatic ring derivative - Google Patents

Bicyclic heteroaromatic ring derivative Download PDF

Info

Publication number
CA3104054A1
CA3104054A1 CA3104054A CA3104054A CA3104054A1 CA 3104054 A1 CA3104054 A1 CA 3104054A1 CA 3104054 A CA3104054 A CA 3104054A CA 3104054 A CA3104054 A CA 3104054A CA 3104054 A1 CA3104054 A1 CA 3104054A1
Authority
CA
Canada
Prior art keywords
group
alkyl group
alkyl
optionally substituted
c6alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3104054A
Other languages
English (en)
French (fr)
Inventor
Masahiko KINEBUCHI
Takekazu KONDOU
Koji Ochiai
Yosuke Nishigaya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Publication of CA3104054A1 publication Critical patent/CA3104054A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3104054A 2018-08-21 2019-08-20 Bicyclic heteroaromatic ring derivative Pending CA3104054A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-154411 2018-08-21
JP2018154411 2018-08-21
PCT/JP2019/032335 WO2020040104A1 (ja) 2018-08-21 2019-08-20 ２環性ヘテロ芳香環誘導体

Publications (1)

Publication Number Publication Date
CA3104054A1 true CA3104054A1 (en) 2020-02-27

Family

ID=69593150

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3104054A Pending CA3104054A1 (en) 2018-08-21 2019-08-20 Bicyclic heteroaromatic ring derivative

Country Status (19)

Country Link
US (1) US11952387B2 (https=)
EP (1) EP3842439A4 (https=)
JP (1) JP7309725B2 (https=)
KR (1) KR20210046649A (https=)
CN (2) CN112752761B (https=)
AU (1) AU2019324089B2 (https=)
BR (1) BR112021002515A2 (https=)
CA (1) CA3104054A1 (https=)
CL (1) CL2020003116A1 (https=)
CO (1) CO2021000512A2 (https=)
IL (1) IL278885A (https=)
MX (1) MX2020013039A (https=)
MY (1) MY200452A (https=)
PH (1) PH12020551991A1 (https=)
SA (1) SA520420914B1 (https=)
SG (1) SG11202012616RA (https=)
TW (1) TWI811428B (https=)
WO (1) WO2020040104A1 (https=)
ZA (1) ZA202101146B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024231436A1 (en) * 2023-05-11 2024-11-14 Arxada Ag Hydrogenation of cyclic ketones

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT65486B (en) 1975-08-28 1978-03-24 Lilly Co Eli Process for the preparation of carbonil-substituted 1-sulfonylbenzimidazoles
JPH0649066B2 (ja) * 1985-02-14 1994-06-29 積水化学工業株式会社 医療用粘着シ−トもしくはテ−プ
FR2687574B1 (fr) * 1992-02-25 1995-05-05 Rhone Poulenc Rorer Sa Nouvelle application therapeutique de derives du pyridylpyrrolothiazole carboxamide.
US5349068A (en) 1992-04-15 1994-09-20 Sterling Winthrop Inc. 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents
JPH07188017A (ja) * 1993-09-30 1995-07-25 Souyaku Gijutsu Kenkyusho:Kk チアジアゾール誘導体を含有する抗ウイルス剤
US5453433A (en) 1994-05-13 1995-09-26 Sterling Winthrop Inc. Thiadiazoles and antipicornaviral compositions
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
JPH11106340A (ja) 1997-10-02 1999-04-20 Sumitomo Pharmaceut Co Ltd Ｓｔａｔ６活性化阻害剤
US6258831B1 (en) * 1999-03-31 2001-07-10 The Procter & Gamble Company Viral treatment
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0321003D0 (en) * 2003-09-09 2003-10-08 Angeletti P Ist Richerche Bio Compounds, compositions and uses
US7229480B2 (en) 2004-02-13 2007-06-12 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
EP2016075A1 (en) 2006-05-03 2009-01-21 AstraZeneca AB Thiazole derivatives and their use as anti-tumour agents
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
HRP20151128T1 (hr) * 2007-09-27 2015-11-20 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Imidazolotiadiazoli za uporabu kao inhibitori protein kinaze
EP2307425B1 (en) * 2008-07-29 2014-03-26 Merck Patent GmbH Imidazothiadiazoles derivatives
CA2735875A1 (en) * 2008-09-03 2010-03-11 Boehringer Ingelheim International Gmbh Use of quinazoline derivatives for the treatment of viral diseases
ES2665277T3 (es) 2009-03-13 2018-04-25 Katholieke Universiteit Leuven K.U. Leuven R&D Análogos de purina y su uso como agentes inmunosupresores
US8815918B2 (en) 2009-04-02 2014-08-26 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
GB201115665D0 (en) 2011-09-09 2011-10-26 Univ Leuven Kath Autoimmune and inflammatory disorder therapy
US9309236B2 (en) 2011-10-05 2016-04-12 The Board Of Trustees Of The Leland Stanford Junior University PI-kinase inhibitors with broad spectrum anti-infective activity
EP3409666A3 (en) 2012-06-07 2019-01-02 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
WO2014078813A1 (en) 2012-11-19 2014-05-22 Irm Llc Compounds and compositions for the treatment of parasitic diseases
SG11201504291SA (en) 2012-12-20 2015-07-30 Ucb Biopharma Sprl Therapeutically active pyrazolo-pyrimidine derivatives
EP3004060B1 (en) 2013-05-30 2019-11-27 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
RU2689788C2 (ru) 2014-01-22 2019-05-29 Куровир Аб ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ СОЕДИНЕНИЙ
JP6678599B2 (ja) 2014-06-13 2020-04-08 ユニバーシティー オブ ロチェスター 小分子排出ポンプ阻害剤
GB201410816D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201410815D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201410817D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D Therapeutic agents
WO2016145045A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
CN107949563B (zh) 2015-06-24 2020-06-05 库洛维公司 治疗中有用的吡唑并[1,5-a]三嗪-4-胺衍生物
EP3118198A1 (en) 2015-07-13 2017-01-18 MMV Medicines for Malaria Venture Anti-malarial agents
WO2017044889A1 (en) 2015-09-10 2017-03-16 The Regents Of The University Of California Lrh-1 modulators
WO2017053192A1 (en) 2015-09-21 2017-03-30 The Board Of Regents Of The University Of Texas System Biomarkers of response to hif-2-alpha inhibition in cancer and methods for the use thereof
GB201517263D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201517264D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201521767D0 (en) 2015-12-10 2016-01-27 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R&D Therapeutic agents
WO2017147526A1 (en) 2016-02-26 2017-08-31 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with anti-infective activity
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
US20190358196A1 (en) 2016-07-27 2019-11-28 Henry C. Lowe Pi 4-kinase inhibitor as a therapeutic for viral hepatitis, cancer, malaria. autoimmune disorders and inflammation, and a radiosensitizer and immunosuppressant

Also Published As

Publication number Publication date
WO2020040104A1 (ja) 2020-02-27
TWI811428B (zh) 2023-08-11
JPWO2020040104A1 (ja) 2021-08-12
EP3842439A4 (en) 2022-04-27
CN118084937A (zh) 2024-05-28
ZA202101146B (en) 2022-07-27
AU2019324089B2 (en) 2024-06-13
BR112021002515A2 (pt) 2021-07-27
KR20210046649A (ko) 2021-04-28
US20220332730A1 (en) 2022-10-20
AU2019324089A1 (en) 2020-12-10
CL2020003116A1 (es) 2021-04-16
SG11202012616RA (en) 2021-02-25
US11952387B2 (en) 2024-04-09
CN112752761A (zh) 2021-05-04
CO2021000512A2 (es) 2021-01-29
JP7309725B2 (ja) 2023-07-18
MY200452A (en) 2023-12-27
CN112752761B (zh) 2024-03-29
IL278885A (en) 2021-01-31
MX2020013039A (es) 2021-02-26
SA520420914B1 (ar) 2023-12-25
TW202021971A (zh) 2020-06-16
PH12020551991A1 (en) 2021-08-02
EP3842439A1 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
AU2019203119B2 (en) Urea derivative or pharmacologically acceptable salt thereof
JP2024517906A (ja) スルホンイミドイル含有ａｔｒ阻害剤化合物
CA3047370A1 (en) Pyran dervatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors
CA2950807A1 (en) Dihydropyrimido fused ring derivative as hbv inhibitor
AU2010201952A1 (en) N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors
AU2007225680A1 (en) Triazole derivative or salt thereof
WO2016203112A1 (en) Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
CA3251124A1 (en) 4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE
CN112689637A (zh) 咪唑并吡啶酮化合物
EP1940823A2 (fr) Dérivés de la 1-amino-phtalazine substituee, leur préparation et leur application en thérapeutique
TW200804323A (en) Derivatives having PPAR agonist activity
WO2002006231A1 (en) Serotonin reuptake inhibitors
CN120752226A (zh) 一类cyp11a1抑制剂化合物及其制备方法和用途
CA3104054A1 (en) Bicyclic heteroaromatic ring derivative
CN117946111A (zh) 一种芳基杂环类Kv1.3抑制剂及其制备方法和用途
HK1207634A1 (en) Substituted phenylcarbamate compounds
WO2017143011A1 (en) Histone demethylase inhibitors
CN121712776A (zh) 驱动蛋白kif18a抑制剂及其应用
RU2798838C2 (ru) Бициклическое гетероароматическое кольцевое производное
TW202440097A (zh) 磺醯胺化合物、其藥物組合物和用途
KR20180118717A (ko) 5-메틸-6-페닐-4,5-디하이드로-2h-피리다진-3-온 유도체
JP6772251B2 (ja) オレキシン受容体拮抗薬の化合物の結晶形およびその製造方法と使用
EP4514808B1 (en) Compositions useful for modulating splicing
HK40051492A (en) Bicyclic heteroaromatic ring derivative
EA048927B1 (ru) Гидроксигетероциклоалканкарбамоильные производные

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240614

D17 Fast track examination accepted

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D17-D161 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PPH RETAINED AFTER REVIEW

Effective date: 20240724

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240726

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20241126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260206